tradingkey.logo
tradingkey.logo
Search

Bio Rad Laboratories Inc

BIOb
Add to Watchlist
321.500USD
+25.010+8.44%
Close 06/26, 16:00ETQuotes delayed by 15 min
8.63BMarket Cap
53.32P/E TTM

More Details of Bio Rad Laboratories Inc Company

Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.

Bio Rad Laboratories Inc Info

Ticker SymbolBIOb
Company nameBio Rad Laboratories Inc
IPO dateMar 17, 1980
CEOSchwartz (Norman D)
Number of employees7700
Security typeOrdinary Share
Fiscal year-endMar 17
Address1000 Alfred Nobel Dr
CityHERCULES
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountryUnited States of America
Postal code94547
Phone15107247000
Websitehttps://www.bio-rad.com/
Ticker SymbolBIOb
IPO dateMar 17, 1980
CEOSchwartz (Norman D)

Company Executives of Bio Rad Laboratories Inc

Name
Name/Position
Position
Shareholding
Change
Mr. Norman D. Schwartz
Mr. Norman D. Schwartz
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
431.47K
+13.21%
Mr. Jeffrey L. (Jeff) Edwards
Mr. Jeffrey L. (Jeff) Edwards
Independent Director
Independent Director
--
--
Mr. Gregory K. (Greg) Hinckley, CPA
Mr. Gregory K. (Greg) Hinckley, CPA
Lead Independent Director
Lead Independent Director
--
--
Ms. Melinda Litherland
Ms. Melinda Litherland
Independent Director
Independent Director
--
--
Mr. Arnold A. Pinkston
Mr. Arnold A. Pinkston
Independent Director
Independent Director
--
--
Mr. Edward Chung
Mr. Edward Chung
Vice President - Investor Relations
Vice President - Investor Relations
--
--
Ms. Allison Schwartz
Ms. Allison Schwartz
Director
Director
--
--
Mr. Roop K. Lakkaraju
Mr. Roop K. Lakkaraju
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Ms. Colleen Corey
Ms. Colleen Corey
Executive Vice President, Global Human Resources
Executive Vice President, Global Human Resources
--
--
Mr. Sedat Evran
Mr. Sedat Evran
Executive Vice President - Global Supply Chain
Executive Vice President - Global Supply Chain
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Norman D. Schwartz
Mr. Norman D. Schwartz
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
431.47K
+13.21%
Mr. Jeffrey L. (Jeff) Edwards
Mr. Jeffrey L. (Jeff) Edwards
Independent Director
Independent Director
--
--
Mr. Gregory K. (Greg) Hinckley, CPA
Mr. Gregory K. (Greg) Hinckley, CPA
Lead Independent Director
Lead Independent Director
--
--
Ms. Melinda Litherland
Ms. Melinda Litherland
Independent Director
Independent Director
--
--
Mr. Arnold A. Pinkston
Mr. Arnold A. Pinkston
Independent Director
Independent Director
--
--
Mr. Edward Chung
Mr. Edward Chung
Vice President - Investor Relations
Vice President - Investor Relations
--
--

FAQs

Who are the top five shareholders of Bio Rad Laboratories Inc?

The top five shareholders of Bio Rad Laboratories Inc are: Mr. Norman D. Schwartz

How many institutions hold shares of Bio Rad Laboratories Inc (BIOb)?

As of 2026Q1, 13 institutions hold shares of Bio Rad Laboratories Inc, with a combined market value of approximately 3.75K, accounting for 0.07% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -232.00.
KeyAI